搜尋結果
西維爾足球會
J. Navas (23')其他比賽
Welcome to the Eisai Official Corporate Website Eisai Co., Ltd. Page.
2024年1月9日 · The U.S. Food and Drug Administration (FDA) granted traditional approval on July 6, 2023. In the U.S., treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.
2024年8月1日 · Eisai’s financial results for the first quarter of fiscal year 2024, including details of LEQEMBI’s revenue, will be disclosed in Eisai's financial disclosure scheduled on August 2, 2024.
Brepacise is a dual-task exercise program that stimulates the body and brain by moving the arms and legs to music while also incorporating intellectual challenges. Eisai developed this product with the review of a physician as an easy and fun introductory exercise for those concerned about their brain health.
2024年7月16日 · Under this agreement, Eisai exclusively licenses the intellectual property rights of fosravuconazole in the given countries/regions to Sato Pharma. Ravuconazole, the active ingredient of fosravuconazole, is an antifungal agent discovered and developed by Eisai.
AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health, Eisai and Biogen.
AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health, Eisai and Biogen.
Sevilla 球隊 相關
廣告Make the Most of Your Trip & Book Today. See Reviews for Over 300,000 Things to Do. Use Reserve Now & Pay Later to Secure the Activities You Don't Want to Miss. Book Now!
